Cell permeable NFAT inhibitory peptide Sim-2-VIVIT inhibits T-cell activation and alleviates allergic airway inflammation and hyper-responsiveness
- Authors
- Choi, Je-Min; Sohn, Jung-Ho; Park, Tae-Yoon; Park, Jung-Won; Lee, Sang-Kyou
- Issue Date
- Apr-2012
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- NFAT; VIVIT; Cell permeable peptide; Asthma
- Citation
- IMMUNOLOGY LETTERS, v.143, no.2, pp.170 - 176
- Indexed
- SCIE
SCOPUS
- Journal Title
- IMMUNOLOGY LETTERS
- Volume
- 143
- Number
- 2
- Start Page
- 170
- End Page
- 176
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/165986
- DOI
- 10.1016/j.imlet.2012.01.016
- ISSN
- 0165-2478
- Abstract
- Nuclear factor of activated T cells (NFAT) is an important transcription factor for the production of interleukin (IL)-2 upon T-cell receptor (TcR) signaling. Therefore, inhibition of the NFAT-carcineurin pathway is an important target for inflammatory disease inhibition and graft rejection. A novel cell permeable peptide (CPP), Sim-2, has been identified from a human transcription factor, and Sim-2-CPP conjugated to beta-galactosidase or EGFP protein was efficiently delivered into cells in vitro and in vivo. A cell permeable form of the NFAT inhibitory peptide VIVIT (Sim-2-VIVIT) was synthesized and showed inhibitory effects on human CD4 or CD8 T-cell activation through NFAT transcriptional activity suppression and IL-2 inhibition. Intranasal administration of the Sim-2-VIVIT peptide in an ovalbumin (OVA)-induced murine asthma model alleviated peribronchial and perivascular infiltration of inflammatory cells in the lung and caused airway remodeling and airway hyper-responsiveness. These results suggest that cell permeable Sim-2-VIVIT peptide has clinical potential as an immunosuppressive agent for inflammatory diseases.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 자연과학대학 > 서울 생명과학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.